BioNTech Sees Unusually High Options Volume (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) was the target of some unusual options trading on Wednesday. Investors bought 2,346 call options on the company. This is an increase of approximately 59% compared to the average daily volume of 1,477 call options.

BioNTech Trading Up 5.8 %

BNTX traded up $5.35 on Wednesday, hitting $97.42. The company had a trading volume of 496,988 shares, compared to its average volume of 629,368. The company’s fifty day moving average price is $90.54 and its 200 day moving average price is $95.84. BioNTech has a 1 year low of $85.21 and a 1 year high of $125.83. The company has a current ratio of 11.38, a quick ratio of 11.16 and a debt-to-equity ratio of 0.01. The firm has a market cap of $23.16 billion, a P/E ratio of 195.96 and a beta of 0.25.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The company had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $2.04 billion. As a group, equities analysts expect that BioNTech will post -1.99 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Truist Financial Corp purchased a new stake in shares of BioNTech in the 4th quarter valued at $1,445,000. Fifth Third Bancorp increased its stake in BioNTech by 3,881.3% during the fourth quarter. Fifth Third Bancorp now owns 16,642 shares of the company’s stock worth $1,756,000 after purchasing an additional 16,224 shares during the period. Bamco Inc. NY lifted its position in shares of BioNTech by 123.1% during the third quarter. Bamco Inc. NY now owns 158,911 shares of the company’s stock worth $17,264,000 after purchasing an additional 87,686 shares in the last quarter. Kestra Private Wealth Services LLC purchased a new position in shares of BioNTech in the fourth quarter valued at approximately $938,000. Finally, abrdn plc acquired a new position in shares of BioNTech in the fourth quarter valued at approximately $10,961,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BNTX has been the topic of a number of research reports. Evercore ISI assumed coverage on BioNTech in a report on Tuesday, May 14th. They issued an “inline” rating and a $100.00 price objective on the stock. The Goldman Sachs Group dropped their price objective on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 28th. JPMorgan Chase & Co. decreased their target price on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a research note on Friday, March 22nd. Canaccord Genuity Group restated a “buy” rating and issued a $171.00 price target on shares of BioNTech in a research report on Thursday, March 21st. Finally, UBS Group reduced their price objective on BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $111.70.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.